Competitor Landscape: CKD-MBD
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the CKD-MBD market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- OPKO appears to be currently focusing resources on the commercialization and continued development of the SHPT therapy Rayaldee (calcifediol ER), which may result in further delays to Alpharens development
- While the main challenge for Velphoro remains the market dominance of branded & generic sevelamer, the real-world evidence from trials like VERIFIE are expected to strengthen the value proposition for VERIFIE and encourage its use over older phosphate binders
- Positive findings from a trial comparing the efficacy of Velphoro and sevelamer carbonate for lowering and maintaining serum phosphate levels in adult Chinese DD-CKD subjects may support a future approval in China, and generate new revenue streams for Vifor.
- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharmas Competitor Landscape
CKD-MBD Pipeline Landscape
CKD-MBD Approved Product Development Landscape
Make an enquiry before buying this Report
Please fill the enquiry form below.